DEEP DIVE

mAbs for malaria vaccine development

Creation date:

11/07/2019

Last modified date:

21/03/2024

This is an active Deep Dive and we welcome your contributions! If you are currently involved or planning research activities on mAbs for malaria vaccine development please contact MESA (mesa@isglobal.org) or add your project to the database.

——

WHO consultation to discuss malaria vaccines and biologicals research and development, with the aim to review the state-of-the-art in malaria vaccine development including new developments in the field, key challenges and opportunities, was convened by WHO in July 2019 [ref].
 
To facilitate the consultation’s work, MESA is compiling a landscape of recent and ongoing research in monoclonal antibodies (mAbs) for malaria vaccine development. mAbs can assist in the development of vaccines by acting as the starting point of ‘Antibody-guided vaccine design’, a new approach for vaccine development and one of the most relevant recent methodological advances in biomedicine. With this approach a panel of newly discovered neutralizing mAbs, from vaccinated or malaria infected humans, are isolated and mapped to find vulnerable epitopes that are used to design immunogens, thus potential vaccine antigens

MESA Track
Total
projects

0 active
MESA Track
Total funding
amount

MESA Track
Project
sites

Research Area

Total Projects

Project Timeline

Research Area

Total Projects

    Project Timeline

    Research Area

    Total Projects

      Project Timeline

      FILTERS

      Reset filters
      Principal Institutions
      Projects|Funding



      Principal Investigators

        Funding Sources

        Principal Institutions

        Principal Investigators

        Funding Sources

        Principal Institutions


        Latest projects